载脂蛋白B、急性冠脉综合征后残余心血管风险及阿利西尤单抗的效应
在ODYSSEY OUTCOMES试验的18 924例近期急性冠脉综合征且优化他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者中,基线载脂蛋白B(apoB)越高,主要不良心血管事件(MACE)发生率越高;阿利西尤单抗在各基线apoB分层均降低MACE,基线越高绝对获益越大;治疗后达到的apoB越低,MACE风险越低,且独立于低密度脂蛋白胆固醇(LDL-C)或非高密度脂蛋白胆固醇(非HDL-C)。
要点
- 基线apoB分层越高,安慰剂组MACE发生率越高,校正LDL-C后趋势仍显著。
- 阿利西尤单抗在各基线apoB分层均降低MACE,基线越高绝对降幅越大。
- 达到apoB≤35 mg/dL可能降低急性冠脉综合征后脂蛋白相关残余风险。
核心结论
- 在近期急性冠脉综合征且致动脉粥样硬化脂蛋白升高的患者中,MACE发生率随基线apoB分层升高而增加。
- 阿利西尤单抗在所有基线apoB分层均降低MACE,基线apoB越高绝对降幅越大。
- 达到的apoB越低,MACE风险越低,且校正达到的LDL-C或非HDL-C后仍独立相关。
研究设计与样本
- ODYSSEY OUTCOMES试验比较PCSK9抑制剂阿利西尤单抗与安慰剂,纳入18 924例近期急性冠脉综合征且优化他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者。
- 主要结局为MACE(冠心病死亡、非致死性心肌梗死、致死/非致死性缺血性卒中、不稳定心绞痛住院)。
- 采用校正Cox比例风险模型和倾向评分匹配模型评估基线或4个月时apoB与MACE的关联。
主要发现
- 中位随访2.8年,安慰剂组基线apoB<75、75-<90、≥90 mg/dL分层MACE发生率分别为3.2(95%CI 2.9-3.6)、4.0(95%CI 3.6-4.5)、5.5(95%CI 5.0-6.1)例/100患者年,趋势P<0.0001。
- 校正LDL-C后基线apoB与MACE趋势P=0.035。
- 阿利西尤单抗组4个月后达到apoB≥50、>35-<50、≤35 mg/dL分层MACE发生率分别为4.26(95%CI 3.78-4.79)、3.09(95%CI 2.69-3.54)、2.41(95%CI 2.11-2.76)例/100患者年。
- 校正达到的LDL-C或非HDL-C后,达到的apoB仍预测MACE,反之则不成立。
临床怎么用
- 在急性冠脉综合征后优化他汀治疗患者中,可考虑检测apoB以评估残余风险。
- 阿利西尤单抗降低MACE的绝对获益在基线apoB较高患者中更大。
- 将apoB降至≤35 mg/dL可能有助于降低脂蛋白相关残余风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. METHODS: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score-matched models. RESULTS: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9-3.6], 4.0 [95% CI, 3.6-4.5], and 5.5 [95% CI, 5.0-6.1] events per 100 patient-years in strata <75, 75-<90, ≥90 mg/dL, respectively; Ptrend<0.0001) and after adjustment for low-density lipoprotein cholesterol (Ptrend=0.035). Higher baseline apoB stratum was associated with greater relative (Ptrend<0.0001) and absolute reduction in MACE with alirocumab versus placebo. In the alirocumab group, the incidence of MACE after month 4 decreased monotonically across decreasing achieved apoB strata (4.26 [95% CI, 3.78-4.79], 3.09 [95% CI, 2.69-3.54], and 2.41 [95% CI, 2.11-2.76] events per 100 patient-years in strata ≥50, >35-<50, and ≤35 mg/dL, respectively). Compared with propensity score-matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol but not vice versa. CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01663402.
引用
- Hagström E, Steg PG, Szarek M, et al. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022. PMID: 35770629. doi:10.1161/CIRCULATIONAHA.121.057807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。